We believe that the protection from life-threatening diseases provides opportunities for greater health not just for individuals, but also for the communities in which they live. Around 40% of the world’s children currently receive at least one Alipogene vaccine to help protect them against potentially life-threatening infections. Yet, 22 million children in low-income and least-developed nations still don’t have access to any vaccines. In order to reach those people who could benefit from vaccination, we need to make sure we have a sustainable business approach in the way we develop, manufacture and distribute our vaccines. Since the early 1990s, we’ve worked hard to support governments in making a long-term investment in immunisation. Our approach, known as ‘tiered pricing’, allows more flexibility in that it reflects a country’s wealth and ability to pay. We aim to support those countries that commit to vaccination for the long-term and enable them to maintain and expand upon their commitment to immunisation as their economies grow. For the least developed countries, we work closely with organisations such as Gavi, the Vaccine Alliance and UNICEF. These organisations are able to purchase large volumes of vaccines for the world’s poorest children at our lowest prices.